949
Views
64
CrossRef citations to date
0
Altmetric
Original Articles

Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa

, , , , , , , , , , & show all
Pages 1-10 | Received 11 Jul 2018, Accepted 11 Nov 2018, Published online: 05 Dec 2018

References

  • ThounaojamADBalakrishnanAMunABDetection and molecular typing of human adenoviruses associated with respiratory illnesses in KeralaJpn. J. Infect. Dis.201669 500 50410.7883/yoken.JJID.2015.414
  • HeoJYet al.Molecular epidemiology of human adenovirus-associated febrile respiratory illness in soldiers, South KoreaEmerg. Infect. Dis.2018241221122710.3201/eid2407.1712226038737
  • IsmailAMet al.Adenoviromics: mining the human adenovirus species D genomeFront. Microbiol.20179217810.3389/fmicb.2018.021
  • ZhengXet al. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern ChinaEmerg Microbes Infect20176e4310.1038/emi.20175520307
  • WangYFet al.Molecular epidemiology and clinical manifestations of adenovirus respiratory infections in Taiwanese ChildrenMedicine201695e357710.1097/MD.00000000000035774863800
  • LiQGZhengQJLiuYHWadellGMolecular epidemiology of adenovirus types 3 and 7 isolated from children with pneumonia in BeijingJ. Med. Virol.20014917017710.1002/(sici)1096-9071(199607)49:33.0.
  • HongJYet al.Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosisClin. Infect. Dis.2001321423142910.1086/320146
  • MandelboimMDrorPAzarRBrombergMMendelsonEAdenovirus infections in hospitalized patients in Israel: epidemiology and molecular characterizationJ. Clin. Microbiol.20114959760110.1128/jcm.00979-103043503
  • GrayGCet al.Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004–2006Clin. Infect. Dis.2007451120113110.1086/5221882064001
  • LuQBet al.Epidemiology of human adenovirus and molecular characterization of human adenovirus 55 in China, 2009–2012Influenza Other Respir. Virus.2014830230810.1111/irv.12232
  • LiXet al. An outbreak of acute respiratory disease in China caused by human adenovirus type B55 in a physical training facilityInt. J. Infect. Dis.20142811712210.1016/j.ijid.2014.06.019
  • Kolavic-GraySAet al.Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studiesClin. Infect. Dis.20023580881810.1086/342573
  • GopalkrishnaVGanorkarNNPatilPRIdentification and molecular characterization of adenovirus types (HAdV-8, HAdV-37, HAdV-4, HAdV-3) in an epidemic of keratoconjunctivitis occurred in Pune, Maharashtra, Western IndiaJ. Med. Virol.2016882100210510.1002/jmv.24565
  • ChengJLet al.Risk factor analysis and molecular epidemiology of respiratory adenovirus infections among children in northern Taiwan, 2009–2013J. Microbiol. Immunol. Infect.20175041842610.1016/j.jmii.2015.08.006
  • KajonAEet al.Adenovirus type 4 respiratory infections among civilian adults, Northeastern United States, 2011–2015Emerg. Infect. Dis.20182420120910.3201/eid2402.1714075782899
  • NarraRet al. Acute respiratory distress syndrome in adenovirus type 4 pneumonia: a case reportJ. Clin. Virol.201681788110.1016/j.jcv.2016.06.005
  • Kalimuddin, S. et al. A report of adult human adenovirus infections in a tertiary hospital. Open Forum Infect. Dis.4, 10.1093/ofid/ofx053 (2017).
  • WeaverEAVaccines within vaccinesHum. Vaccin. Immunother.20131054455610.4161/hv.272384130277
  • SprangersMCet al.Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectorsJ. Clin. Microbiol.2003415046505210.1128/jcm.41.11.5046-5052.2003262545
  • AbbinkPet al.Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and DJ. Virol.2007814654466310.1128/JVI.02696-061900173
  • NwanegboEet al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United StatesClin. Vacc. Immunol.20041135135710.1128/cdli.11.2.351-357.2004
  • MastTCet al.International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trialsVaccine20102895095710.1016/j.vaccine.2009.10.145
  • HuangDet al.The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in ChinaArch. Virol.20151601125113010.1007/s00705-015-2333-24369289
  • YuBet al.A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011Virol. J.2012928710.1186/1743-422X-9-2873515344
  • SunCet al. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern ChinaVaccine2011293837384110.1016/j.vaccine.2011.03.042
  • Aste-AmézagaMet al.Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccinesHum. Gene Ther.20041529330410.1089/104303404322886147
  • WigandRPitfalls in the identification of adenovirusesJ. Virol. Methods19871616116910.1016/0166-0934(87)90001-2
  • KuschnerRAet al. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruitsVaccine2013312963297110.1016/j.vaccine.2013.04.035
  • YangWXet al.Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditionsVaccine2016345579558610.1016/j.vaccine.2016.09.043
  • AppaiahgariMBSainiMRauthanMJyotiVratiSImmunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitisMicrobes Infect.200689210410.1016/j.micinf.2005.05.023
  • ZhuFCet al.Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trialLancet20153852272227910.1016/s0140-6736(15)60553-0
  • FengYet al.An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and Rhesus macaquesEmerg. Microbes Infect.2018710.1038/s41426-018-0102-55988821
  • LiJXet al.Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trialLancet Glob. Health20175e324e33410.1016/s2214-109x(16)30367-9
  • ZhuFCet al.Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trialLancet201738962162810.1016/S0140-6736(16)32617-4
  • SchmttzHWigandRHeinrichWWorldwide epidemiology of human adenovirus infectionsAm. J. Epidemiol.198311745546610.1093/oxfordjournals.aje.a113563